Stephens Assumes MaxCyte Inc. (MXCT) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MXCT Hot Sheet
Price: $1.39 -4.79%
Rating Summary:
4 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
4 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Stephens analyst Hannah Helfey assumes coverage on MaxCyte Inc. (NASDAQ: MXCT) with a Overweight rating and a price target of $6.00.
For an analyst ratings summary and ratings history on MaxCyte Inc. click here. For more ratings news on MaxCyte Inc. click here.
Shares of MaxCyte Inc. closed at $2.02 yesterday.
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- BMO Capital Starts Astera Labs (ALAB) at Outperform
- Freedom Broker Starts Limoneira Company (LMNR) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
